CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

J. M. Michot; R. Bouabdallah; J. K. Doorduijn; U. Vitolo; M. J. Kersten; A. Chiappella; P. L. Zinzani; M. Pourdehnad; Z. Nikolova; V. Ribrag

doi:10.1093/annonc/mdy048.006

CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

J. M. Michot
, R. Bouabdallah
, J. K. Doorduijn
, U. Vitolo
, M. J. Kersten
, A. Chiappella
, P. L. Zinzani
, M. Pourdehnad
, Z. Nikolova
, V. Ribrag

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	iii9
Journal	Annals of oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy048.006
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdy048.006

Cite this

Michot, J. M., Bouabdallah, R., Doorduijn, J. K., Vitolo, U., Kersten, M. J., Chiappella, A., Zinzani, P. L., Pourdehnad, M., Nikolova, Z., & Ribrag, V. (2018). CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Annals of oncology, 29, iii9. https://doi.org/10.1093/annonc/mdy048.006

@article{9c4e656fa2f549e1ad304f449b12ba55,

title = "CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)",

author = "Michot, \{J. M.\} and R. Bouabdallah and Doorduijn, \{J. K.\} and U. Vitolo and Kersten, \{M. J.\} and A. Chiappella and Zinzani, \{P. L.\} and M. Pourdehnad and Z. Nikolova and V. Ribrag",

year = "2018",

doi = "10.1093/annonc/mdy048.006",

language = "English",

volume = "29",

pages = "iii9",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Michot, JM, Bouabdallah, R, Doorduijn, JK, Vitolo, U, Kersten, MJ, Chiappella, A, Zinzani, PL, Pourdehnad, M, Nikolova, Z & Ribrag, V 2018, 'CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)', Annals of oncology, vol. 29, pp. iii9. https://doi.org/10.1093/annonc/mdy048.006

TY - JOUR

T1 - CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

AU - Michot, J. M.

AU - Bouabdallah, R.

AU - Doorduijn, J. K.

AU - Vitolo, U.

AU - Kersten, M. J.

AU - Chiappella, A.

AU - Zinzani, P. L.

AU - Pourdehnad, M.

AU - Nikolova, Z.

AU - Ribrag, V.

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85083531122&origin=inward

U2 - 10.1093/annonc/mdy048.006

DO - 10.1093/annonc/mdy048.006

M3 - Article

SN - 0923-7534

VL - 29

SP - iii9

JO - Annals of oncology

JF - Annals of oncology

ER -

CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

UN SDGs

Access to Document

Other files and links

Cite this